OBJECTIVE: The purpose of the present study was to investigate the effects of differences in social demographic factors and domain-specific sedentary behaviour and health-related quality of life by age in Japanese living overseas.
METHODS: We surveyed 109 participants by self-entry questionnaire for social demographic factors and domain-specific sedentary behaviour by life scenario and by Short Form-36 (SF-36) for healthrelated quality of life. The subjects were divided into the ≥65 years group and <65 years group.
RESULTS: Significant differences were noted in age, employment, alcohol intake, and marital status between the groups, whereas none were noted for transportation, driving, television viewing, and smartphone/personal computer use. Work time and total sitting time of sedentary behaviour were higher, and leisure-time activity and SF-36 Mental Component Score for health-related quality of life were lower in the <65 years group.
CONCLUSION: By assessing differences in social demographic factors and discouraging sedentary behaviour, sitting time in overseas-dwelling Japanese residents may be reduced, and effective strategies to improve health-related quality of life can be developed to combat such behaviour.
METHODS: Based on the retrospective analysis of payment data made available by all 92 pharmaceutical companies in Japan, this study evaluated the magnitude and trend of financial relationships between all board-certified Japanese respiratory specialists and pharmaceutical companies between 2016 and 2019. Magnitude and prevalence of payments for specialists were analyzed descriptively. The payment trends were assessed using the generalized estimating equations for the payment per specialist and the number of specialists with payments.
RESULTS: Among all 7,114 respiratory specialists certified as of August 2021, 4,413 (62.0%) received a total of USD 53,547,391 and 74,195 counts from 72 (78.3%) pharmaceutical companies between 2016 and 2019. The median (interquartile range) 4-year combined payment values per specialist were USD 2,210 (USD 715-8,178). At maximum, one specialist received USD 495,332 personal payments over the 4 years. Both payments per specialist and number of specialists with payments significantly increased during the 4-year period, with 7.8% (95% CI: 5.5-9.8; p < 0.001) in payments and 1.5% (95% CI: 0.61-2.4; p = 0.001) in number of specialists with payments, respectively.
CONCLUSION: The majority of respiratory specialists had increasingly received more personal payments from pharmaceutical companies for the reimbursement of lecturing, consulting, and writing between 2016 and 2019. These increasing financial relationships with pharmaceutical companies might cause conflicts of interest among respiratory physicians.